Genvoya

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

элвитегравир, кобицистат, эмтрицитабин, Тенофовир alafenamide

Available from:

Gilead Sciences Ireland UC

ATC code:

J05AR

INN (International Name):

elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide

Therapeutic group:

Antivirusni lijekovi za sustavnu uporabu

Therapeutic area:

HIV infekcije

Therapeutic indications:

Genvoya je indiciran za liječenje odraslih i adolescenata (u dobi od 12 godina i stariji sa tjelesne težine najmanje 35 kg) zaraženih virusom humane imunodeficijencije (HIV-a 1) 1 bez bilo koje poznate mutacija povezanih s rezistencijom na inhibitora integraze, emtricitabin ili tenofovir.

Product summary:

Revision: 27

Authorization status:

odobren

Authorization date:

2015-11-19

Patient Information leaflet

                                47
B. UPUTA O LIJEKU
48
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
GENVOYA 150 MG/150 MG/200 MG/10 MG FILMOM OBLOŽENE TABLETE
GENVOYA 90 MG/90 MG/120 MG/6 MG FILMOM OBLOŽENE TABLETE
elvitegravir/kobicistat/emtricitabin/tenofoviralafenamid
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Genvoya i za što se koristi
2.
Što morate znati prije nego počnete uzimati lijek Genvoya
3.
Kako uzimati lijek Genvoya
4.
Moguće nuspojave
5.
Kako čuvati lijek Genvoya
6.
Sadržaj pakiranja i druge informacije
AKO JE LIJEK GENVOYA PROPISAN VAŠEM DJETETU, SVE INFORMACIJE IZ OVE
UPUTE O LIJEKU ODNOSE SE NA
VAŠE DIJETE (UMJESTO RIJEČI „VAMA“ ČITAJTE „VAŠEM
DJETETU“_). _
1.
ŠTO JE GENVOYA I ZA ŠTO SE KORISTI
Genvoya sadrži četiri djelatne tvari:
•
ELVITEGRAVIR
, antiretrovirusni lijek poznat kao inhibitor integraze
•
KOBICISTAT
, pojačivač učinaka elvitegravira
•
EMTRICITABIN
, antiretrovirusni lijek poznat kao nukleozidni inhibitor reverzne
transkriptaze
(NRTI)
•
TENOFOVIRALAFENAMID
, antiretrovirusni lijek poznat kao nukleotidni inhibitor reverzne
transkriptaze (NtRTI).
Genvoya je jedna tableta za
LIJEČENJE INFEKCIJE VIRUSOM HUMANE IMUNODEFICIJENCIJE 1 (HIV-1)
u
odraslih, adolescenata i djece u dobi od 2 godine i starijih, koji
imaju tjelesnu težinu od najmanje
14 kg.
Genvoya smanjuje količinu HIV-a u Vašem tijelu. To će poboljšati
Vaš imunološki sustav i smanjiti
rizik od razvoja bolesti povezanih s HIV infekcijom.
2.
ŠTO MORATE ZNATI PRIJE NEGO 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Genvoya 150 mg/150 mg/200 mg/10 mg filmom obložene tablete
Genvoya 90 mg/90 mg/120 mg/6 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Genvoya 150 mg/150 mg/200 mg/10 mg filmom obložene tablete
Jedna tableta sadrži 150 mg elvitegravira, 150 mg kobicistata, 200 mg
emtricitabina i
tenofoviralafenamidfumarata u količini koja odgovara 10 mg
tenofoviralafenamida.
Pomoćna(e) tvar(i) s poznatim učinkom
Jedna tableta sadrži 58 mg laktoze (u obliku hidrata).
Genvoya 90 mg/90 mg/120 mg/6 mg filmom obložene tablete
Jedna tableta sadrži 90 mg elvitegravira, 90 mg kobicistata, 120 mg
emtricitabina i
tenofoviralafenamidfumarata u količini koja odgovara 6 mg
tenofoviralafenamida.
Pomoćna(e) tvar(i) s poznatim učinkom
Jedna tableta sadrži 35 mg laktoze (u obliku hidrata).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta).
Genvoya 150 mg/150 mg/200 mg/10 mg filmom obložene tablete
Zelena filmom obložena tableta u obliku kapsule veličine 19 mm x 8,5
mm, s utisnutom oznakom
„GSI“ na jednoj strani tablete i „510“ na drugoj strani
tablete.
Genvoya 90 mg/90 mg/120 mg/6 mg filmom obložene tablete
Zelena filmom obložena tableta u obliku kapsule veličine 16 mm x 7
mm, s utisnutom oznakom „GSI“
na jednoj strani tablete i urezom na drugoj strani tablete.
Urez služi samo kako bi se olakšalo lomljenje tablete radi lakšeg
gutanja, a ne da bi se podijelila na
jednake doze.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Genvoya je indicirana za liječenje osoba zaraženih virusom humane
imunodeficijencije tipa 1 (HIV-1)
bez ijedne poznate mutacije povezane s rezistencijom na skupinu
inhibitora integraze, emtricitabin ili
tenofovir kod odraslih i pedijatrijskih bolesnika u dobi od 2 godine i
starijih, s tjelesnom težinom od
najmanje 14 kg.
Vidjeti dijelove 4.2 i 5.1.
3
4.2
DOZIRANJE I NAČIN PRIMJENE
Terapiju mora započeti liječnik s iskustvom u liječenju infekcije
HIV-o
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-11-2022
Public Assessment Report Public Assessment Report Bulgarian 08-11-2022
Patient Information leaflet Patient Information leaflet Spanish 28-11-2022
Public Assessment Report Public Assessment Report Spanish 08-11-2022
Patient Information leaflet Patient Information leaflet Czech 28-11-2022
Public Assessment Report Public Assessment Report Czech 08-11-2022
Patient Information leaflet Patient Information leaflet Danish 28-11-2022
Public Assessment Report Public Assessment Report Danish 08-11-2022
Patient Information leaflet Patient Information leaflet German 28-11-2022
Public Assessment Report Public Assessment Report German 08-11-2022
Patient Information leaflet Patient Information leaflet Estonian 28-11-2022
Public Assessment Report Public Assessment Report Estonian 08-11-2022
Patient Information leaflet Patient Information leaflet Greek 28-11-2022
Public Assessment Report Public Assessment Report Greek 08-11-2022
Patient Information leaflet Patient Information leaflet English 02-09-2022
Public Assessment Report Public Assessment Report English 23-01-2018
Patient Information leaflet Patient Information leaflet French 28-11-2022
Public Assessment Report Public Assessment Report French 08-11-2022
Patient Information leaflet Patient Information leaflet Italian 28-11-2022
Public Assessment Report Public Assessment Report Italian 08-11-2022
Patient Information leaflet Patient Information leaflet Latvian 28-11-2022
Public Assessment Report Public Assessment Report Latvian 08-11-2022
Patient Information leaflet Patient Information leaflet Lithuanian 28-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-11-2022
Public Assessment Report Public Assessment Report Lithuanian 08-11-2022
Patient Information leaflet Patient Information leaflet Hungarian 28-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 28-11-2022
Public Assessment Report Public Assessment Report Hungarian 08-11-2022
Patient Information leaflet Patient Information leaflet Maltese 28-11-2022
Public Assessment Report Public Assessment Report Maltese 08-11-2022
Patient Information leaflet Patient Information leaflet Dutch 28-11-2022
Public Assessment Report Public Assessment Report Dutch 08-11-2022
Patient Information leaflet Patient Information leaflet Polish 28-11-2022
Public Assessment Report Public Assessment Report Polish 08-11-2022
Patient Information leaflet Patient Information leaflet Portuguese 28-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 28-11-2022
Public Assessment Report Public Assessment Report Portuguese 08-11-2022
Patient Information leaflet Patient Information leaflet Romanian 28-11-2022
Public Assessment Report Public Assessment Report Romanian 08-11-2022
Patient Information leaflet Patient Information leaflet Slovak 28-11-2022
Public Assessment Report Public Assessment Report Slovak 08-11-2022
Patient Information leaflet Patient Information leaflet Slovenian 28-11-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 28-11-2022
Public Assessment Report Public Assessment Report Slovenian 08-11-2022
Patient Information leaflet Patient Information leaflet Finnish 28-11-2022
Public Assessment Report Public Assessment Report Finnish 08-11-2022
Patient Information leaflet Patient Information leaflet Swedish 28-11-2022
Public Assessment Report Public Assessment Report Swedish 08-11-2022
Patient Information leaflet Patient Information leaflet Norwegian 28-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 28-11-2022
Patient Information leaflet Patient Information leaflet Icelandic 28-11-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 28-11-2022

View documents history